XML 68 R57.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Assets and Liabilities Measured at Fair Value (Details) $ in Thousands |  |  | 1 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | ---
Jul. 05, 2016 USD ($) | Sep. 30, 2015 USD ($) | Nov. 30, 2013 USD ($) | Dec. 31, 2016 USD ($) | Dec. 31, 2015 USD ($) item | Dec. 31, 2014 USD ($) | Sep. 30, 2016 USD ($) | Jun. 30, 2016 USD ($) | Oct. 31, 2015 USD ($)
Financial assets and liabilities subject to fair value measurements |  |  |  |  |  |  |  |  |
Transfer of assets from Level 1 to Level 2 |  |  |  | $ 0 |  |  |  |  |
Transfer of assets from Level 2 to Level 1 |  |  |  | 0 |  |  |  |  |
Assets: |  |  |  |  |  |  |  |  |
Fair value of assets |  |  |  | 144,754 | $ 145,206 |  |  |  |
Trading securities |  |  |  | 1,500 | 700 |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Contingent consideration payable |  |  |  | 269,722 | 274,077 |  |  |  |
Derivative liability |  |  |  | 265 |  |  |  |  |
Deferred compensation plan liability |  |  |  | 1,479 | 667 |  |  |  |
Fair value of liabilities |  |  |  | 271,466 | 274,744 |  |  |  |
Contingent consideration payable |  |  |  | 269,722 | 274,077 |  |  |  |
Contingent consideration payable |  |  |  |  |  |  |  |  |
Balance, beginning of the period |  |  |  | 274,077 | 10,700 |  |  |  |
Additions, from business acquisitions |  |  |  |  | 259,000 |  |  |  |
Payment of contingent consideration in cash |  |  |  | (5,000) |  |  |  |  |
Payment of contingent consideration in stock |  |  |  | (6,115) |  |  |  |  |
Unrealized change in fair value change during the period, included in Statement of Operations |  |  |  | 6,760 | 4,377 | $ 100 |  |  |
Balance, end of the period |  |  |  | 269,722 | $ 274,077 | $ 10,700 |  |  |
Foreign Currency Exchange Rate Exposure |  |  |  |  |  |  |  |  |
Number Of Forward Contracts | item |  |  |  |  | 0 |  |  |  |
Non-cash changes in the fair value of derivative liability |  |  |  | (265) |  |  |  |  |
Other current liabilities |  |  |  |  |  |  |  |  |
Foreign Currency Exchange Rate Exposure |  |  |  |  |  |  |  |  |
Derivative liabilities |  |  |  | 265 |  |  | $ 300 |  |
Callidus |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Contingent consideration payable |  |  | $ 10,600 | 9,700 |  |  |  |  |
Contingent consideration payable |  |  | $ 10,600 | 9,700 |  |  |  |  |
Discount rate (as a percent) |  |  | 13.50% |  |  |  |  |  |
Scioderm |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Contingent consideration payable |  | $ 259,000 |  | 260,000 |  |  |  |  |
Contingent consideration payable |  | $ 259,000 |  | 260,000 |  |  |  |  |
MiaMed Inc |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Contingent consideration payable upon achievement of milestones | $ 83,000 |  |  |  |  |  |  |  |
Potential aggregate deal value | 89,500 |  |  |  |  |  |  |  |
Clinical and Regulatory Approval milestones | Callidus |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Contingent consideration payable |  |  |  | 9,300 |  |  |  |  |
Contingent consideration payable |  |  |  | 9,300 |  |  |  |  |
Clinical and Regulatory Approval milestones | Scioderm |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Contingent consideration payable |  |  |  | 237,200 |  |  |  |  |
Contingent consideration payable |  |  |  | 237,200 |  |  |  |  |
Revenue-based milestones | Scioderm |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Contingent consideration payable |  |  |  | 22,800 |  |  |  |  |
Contingent consideration payable |  |  |  | 22,800 |  |  |  |  |
Minimum | Clinical and Regulatory Approval milestones | Scioderm |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Discount rate (as a percent) |  | 0.40% |  |  |  |  |  |  |
Minimum | Revenue-based milestones | Scioderm |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Discount rate (as a percent) |  | 1.00% |  |  |  |  |  |  |
Maximum | Clinical and Regulatory Approval milestones | Scioderm |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Discount rate (as a percent) |  | 1.10% |  |  |  |  |  |  |
Maximum | Revenue-based milestones | Scioderm |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Discount rate (as a percent) |  | 2.20% |  |  |  |  |  |  |
Maximum | Clinical, Regulatory and Commercial milestones | MiaMed Inc |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Contingent consideration payable upon achievement of milestones | $ 83,000 |  |  |  |  |  |  |  |
Commercial paper |  |  |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |  |  |
Fair value of assets |  |  |  | 68,390 | $ 25,724 |  |  |  |
Corporate debt securities |  |  |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |  |  |
Fair value of assets |  |  |  | 74,535 | 118,474 |  |  |  |
Certificate of deposit |  |  |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |  |  |
Fair value of assets |  |  |  |  | 350 |  |  |  |
Market exchanged mutual funds |  |  |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |  |  |
Fair value of assets |  |  |  | 1,829 | 658 |  |  |  |
Level 2 |  |  |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |  |  |
Fair value of assets |  |  |  | 144,754 | 145,206 |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Derivative liability |  |  |  | 265 |  |  |  |  |
Deferred compensation plan liability |  |  |  | 1,479 | 667 |  |  |  |
Fair value of liabilities |  |  |  | 1,744 | 667 |  |  |  |
Level 2 | Commercial paper |  |  |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |  |  |
Fair value of assets |  |  |  | 68,390 | 25,724 |  |  |  |
Level 2 | Corporate debt securities |  |  |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |  |  |
Fair value of assets |  |  |  | 74,535 | 118,474 |  |  |  |
Level 2 | Certificate of deposit |  |  |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |  |  |
Fair value of assets |  |  |  |  | 350 |  |  |  |
Level 2 | Market exchanged mutual funds |  |  |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |  |  |
Fair value of assets |  |  |  | 1,829 | 658 |  |  |  |
Level 3 |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Contingent consideration payable |  |  |  | 269,722 | 274,077 |  |  |  |
Fair value of liabilities |  |  |  | 269,722 | 274,077 |  |  |  |
Contingent consideration payable |  |  |  | $ 269,722 | $ 274,077 |  |  |  |
Level 3 | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Discount rate (as a percent) |  |  |  | 12.50% |  |  |  |  |
Level 3 | Revenue-based milestones | Monte Carlo | Scioderm |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Probability of achievement of milestones (as a percent) |  |  |  | 66.50% |  |  |  |  |
Revenue volatility (as a percent) |  |  |  | 58.00% |  |  |  |  |
Level 3 | Minimum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Probability of achievement of milestones (as a percent) |  |  |  | 30.40% |  |  |  |  |
Level 3 | Minimum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Scioderm |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Discount rate (as a percent) |  |  |  | 0.62% |  |  |  |  |
Probability of achievement of milestones (as a percent) |  |  |  | 66.50% |  |  |  |  |
Level 3 | Minimum | Revenue-based milestones | Monte Carlo | Scioderm |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Discount rate (as a percent) |  |  |  | 1.47% |  |  |  |  |
Level 3 | Maximum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Probability of achievement of milestones (as a percent) |  |  |  | 42.80% |  |  |  |  |
Level 3 | Maximum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Scioderm |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Discount rate (as a percent) |  |  |  | 3.80% |  |  |  |  |
Probability of achievement of milestones (as a percent) |  |  |  | 100.00% |  |  |  |  |
Level 3 | Maximum | Revenue-based milestones | Monte Carlo | Scioderm |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Discount rate (as a percent) |  |  |  | 2.55% |  |  |  |  |
Redmile Group | Note And Warrant Agreement 2015 [Member] | Private Placement Purchase Agreement |  |  |  |  |  |  |  |  |
Financial assets and liabilities subject to fair value measurements |  |  |  |  |  |  |  |  |
Proceeds from note and warrant purchase agreement |  |  |  |  |  |  |  |  | $ 50,000
Redmile Group | Additional Note and Warrant Agreement June 2016 | Beneficial Owner | Private Placement Purchase Agreement |  |  |  |  |  |  |  |  |
Financial assets and liabilities subject to fair value measurements |  |  |  |  |  |  |  |  |
Proceeds from note and warrant purchase agreement |  |  |  |  |  |  |  | $ 30,000 |

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Includes payments for achievement of certain clinical, regulatory and commercial milestones. + References No definition available. + Details
Name: | fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contingent consideration payable rollforward. + References No definition available. + Details
Name: | fold_BusinessCombinationContingentConsiderationLiabilityRollForward
Namespace Prefix: | fold_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of contingent consideration payable in a business combination upon achievement of certain clinical, regulatory and commercial milestones. + References No definition available. + Details
Name: | fold_BusinessCombinationContingentConsiderationMilestones
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of assumed revenue volatility, used as an input to measure fair value. + References No definition available. + Details
Name: | fold_FairValueAssumptionsRevenueVolatilityRate
Namespace Prefix: | fold_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of likelihood that milestones will be achieved, used as an input to measure fair value. + References No definition available. + Details
Name: | fold_FairValueInputsProbabilityOfAchievementOfMilestones
Namespace Prefix: | fold_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase (decrease) from business acquisitions of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + References No definition available. + Details
Name: | fold_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This element represents the number of forward contracts negotiated to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date. + References No definition available. + Details
Name: | fold_NumberOfForwardContracts
Namespace Prefix: | fold_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow associated with the payment of contingent consideration liabilities. + References No definition available. + Details
Name: | fold_PaymentOfContingentConsideration
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details
Name: | us-gaap_AssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_AssetsFairValueDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph b -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Face (par) amount of debt instrument at time of issuance. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399 + Details
Name: | us-gaap_DebtInstrumentFaceAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements. + References No definition available. + Details
Name: | us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 860 -SubTopic 20 -Section 50 -Paragraph 4D -Subparagraph (c)(2) -URI http://asc.fasb.org/extlink&oid=51814546&loc=SL51823488-111719 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Subparagraph (a),(c) -URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624163-113959 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 55 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=51825145&loc=SL20226000-175313 + Details
Name: | us-gaap_DerivativeFairValueOfDerivativeLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Liabilities -URI http://asc.fasb.org/extlink&oid=6509677 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611 + Details
Name: | us-gaap_DerivativeLiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bb) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bb) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueInputsDiscountRate
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of unrealized gain (loss) recognized in the income statement for a financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value of financial and nonfinancial obligations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details
Name: | us-gaap_LiabilitiesFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_LiabilitiesFairValueDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of investments in debt and equity securities and other forms of securities that provide ownership interests classified as trading. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26626-111562 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.4) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26610-111562 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Trading Securities -URI http://asc.fasb.org/extlink&oid=6526789 + Details
Name: | us-gaap_TradingSecurities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CertificatesOfDepositMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=fold_MarketExchangedMutualFundsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=fold_MonteCarloMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=fold_NoteAndWarrantAgreement2015Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fold_PrivatePlacementPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=fold_AdditionalNoteAndWarrantAgreementJune2016Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |